Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
Massachusetts General Hospital · The University of Melbourne · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
133
total citations
- FWCI
- 50.13
- Percentile
- 100%
- References
- 38
Citations per year
Authors
27- JSJeremy S AbramsonCorresponding
Massachusetts General Hospital
- MKMatthew Ku
The University of Melbourne, St Vincent's Hospital Melbourne
- MPMark P. Hertzberg
Prince of Wales Hospital
- HHHuiqiang Huang
Sun Yat-sen University, Roche (Canada), Sun Yat-sen University Cancer Center
- CPChristopher P. Fox
University of Nottingham
Topics & keywords
Topics
Keywords
- Oxaliplatin
- Rituximab
- Medicine
- Refractory (planetary science)
- Gemcitabine
- Open label
- Diffuse large B-cell lymphoma
- Internal medicine
No related works found for this paper.